Cas:2859-88-3 7-hydroxy-2-methyl-3-phenylchromen-4-one manufacturer & supplier

We serve Chemical Name:7-hydroxy-2-methyl-3-phenylchromen-4-one CAS:2859-88-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

7-hydroxy-2-methyl-3-phenylchromen-4-one

Chemical Name:7-hydroxy-2-methyl-3-phenylchromen-4-one
CAS.NO:2859-88-3
Synonyms:7-hydroxy-2-methylisoflavone;7-hydroxy-2-methyl-3-phenyl-<4H>-1-benzopyran-4-one;7-Hydroxy-2-methyl-3-phenyl-4H-chromen-4-one;2-methyl-7-hydroxyisoflavone;7-Hydroxy-2-methyl-3-phenyl-chromen-4-one;2-Methyl-7-hydroxy-3-phenyl-(4H)-1-benzopyran-7-one;7-hydroxy-2-methyl-3-phenylchromone
Molecular Formula:C16H12O3
Molecular Weight:252.26500
HS Code:2914400090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:452.2ºC at 760mmHg
Density:1.289g/cm3
Index of Refraction:1.643
PSA:50.44000
Exact Mass:252.07900
LogP:3.47400

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 7-hydroxy-2-methylisoflavone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-hydroxy-2-methyl-3-phenylchromone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-hydroxy-2-methyl-3-phenylchromone Use and application,7-hydroxy-2-methyl-3-phenyl-&lt technical grade,usp/ep/jp grade.


Related News: GBS is a rare but potentially life-threatening disorder in which the body’s immune system attacks nerve cells. The condition has been associated with the use of other widely used vaccines, such as GlaxoSmithKline’s Shingrix. N,N-Bis[4-(diethylamino)phenyl]-N’,N’-diethyl-1,4-benzenediamine hexafluorophosphate manufacturers It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. CYTOSINE-13C,15N2 suppliers In 2021, the combo has raked in $818 million in the first half of the year alone for Novartis, a number that is already up 11% from last year. Comparatively, Roche reported $218 million in sales of Zelboraf in 2016, and revenue was not reported in its most recent mid-year update. 3-(Benzylamino)propan-1-ol vendor & factory.